Company intelligence / Profile preview

ANTEXGROUP

Gaithersburg, Maryland, United Statesantexgroup.it ↗

Ownership: Private
Development stage: Other

Overview

Prior to acquisition, Antex Biologics had two antibiotic candidates in human clinical trials targeting drug-resistant bacteria. Their lead compound AP158 showed efficacy against mupirocin-resistant Staphylococcus aureus strains. The company maintained strategic alliances with GlaxoSmithKline, Aventis Pasteur, and the US Department of Defense.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule (antibiotics)
Industry: Biotech

Partnerships

GlaxoSmithKlineAventis PasteurUS Department of Defense

Beyond the preview

Go deeper on ANTEXGROUP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANTEXGROUP.

Explore the full profile